Dr. Wang is a neurotrauma researcher and neuroscientist since the late 1990’s. Spanning his career in pharmaceutical company sector (Parker-Davis & Pfizer), the Morehouse School of Medicine/ University of Florida/ and biotechnology companies that he co-founded  (Banyan Biomarkers, and Gryphon Bio), his research interest is translational research on biomarkers and new therapies for traumatic brain injury (TBI), spinal cord injury, post-traumatic epilepsy, and chronic traumatic encephalopathy. Two acute TBI blood-based protein biomarkers (UCH-L1/GFAP) he co-discovered and conducted research and development on had resulted in FDA and European Medicines Agency (EMA) regulatory clearance as the first in vitro diagnostic blood tests for mild TBI patients with lesions.  He also holds leadership positions in National Neurotrauma society, International Brain Injury Association and the Academy for Multidisciplinary Neurotraumatology, TBI initiatives such as International TBI Research Initiative (InTBIR), and multicenter TBI consortium studies (e.g. TRACK-TBI, CENTER-TBI, TOP-NT). Dr. Wang is Principal Investigator of multiple research grants funded by National Institute of Health, Department of Defense, Veterans Affairs and other research foundations. He has also authored over 320 peer-reviewed publications and edited /co-edited 6 scientific books.  

 In the Fall of 2022, Dr. Wang and his research group moved from University of Florida to join the Department of Neurobiology and the Neuroscience institute of Morehouse School of Medicine (MSM) In addition to being the Professor & Vice-Chair for Research of the Department of Neurobiology and the Associate Director of Research Innovation of the Neuroscience institute, , Dr. Wang is the Director of the Center for Neurotrauma, Multiomics & Biomarkers (CNMB) at MSM, under which he and his team will continue innovative biomarker discovery and clinical validation works using animal models as well as biosamples from human clinical studies  in the area of TBI, spinal cord injury, post-traumatic epilepsy, chronic traumatic encephalopathy, post-traumatic epilepsy and Alzheimer’s disease. Dr. Wang believes that disease biomarker research indeed holds the key to development of novel brain disease diagnostics tests and as patient management tools, as well as the facilitation of the rapid development of novel therapeutics for these tough-to-treat CNS diseases.

Research Interests:

Brain Sciences and tackling Brain Disorders